# Acute Olanzapine and Lipid Response

> **NCT04181385** · PHASE2,PHASE3 · UNKNOWN · sponsor: **University Health Network, Toronto** · enrollment: 15 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Olanzapine 10 milligram
- **DRUG:** Bromocriptine 5 milligram
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT04181385
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-01
- **Primary completion:** 2020-01-01
- **Final completion:** 2020-06-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2019-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04181385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04181385, "Acute Olanzapine and Lipid Response". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04181385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*